APA (7th ed.) Citation

Niger, M., Nichetti, F., Fornaro, L., Pircher, C., Morano, F., Palermo, F., . . . Delliponti, L. (2024). A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-12225-6

Chicago Style (17th ed.) Citation

Niger, Monica, et al. "A Phase II/III Randomized Clinical Trial of CisPlatin PlUs Gemcitabine and Nabpaclitaxel (GAP) as PReoperative Chemotherapy Versus Immediate Resection in PatIents with ResecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-12225-6.

MLA (9th ed.) Citation

Niger, Monica, et al. "A Phase II/III Randomized Clinical Trial of CisPlatin PlUs Gemcitabine and Nabpaclitaxel (GAP) as PReoperative Chemotherapy Versus Immediate Resection in PatIents with ResecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-12225-6.